Documenting research in scientific articles: Guidelines for authors. Reporting research designs and activities

Chest

Volumn 130, Issue 4, 2006, Pages 1263-1268

  Lang, Tom ^a,b  

^a Tom Lang Communications and Training   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALYTICAL ERROR; CONFOUNDING VARIABLE; COVARIANCE; DATA ANALYSIS; DATA EXTRACTION; DATA SYNTHESIS; EVALUATION; HUMAN; MEDICAL LITERATURE; MEDICAL RESEARCH; METHODOLOGY; OUTCOME ASSESSMENT; PATIENT SELECTION; PLANNING; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SAMPLE SIZE; STATISTICAL ANALYSIS; VALIDATION PROCESS;

EID: 33750059146     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.130.4.1263     Document Type: Article

References (36)

1. Lang TA, Secic M. How to report statistics in medicine. 2nd ed. Philadelphia, PA: American College of Physicians, 2006
2. Moher D, Schulz K, Altman DG, for the CONSORT Group. CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. Ann Intern Med 2001; 134:657-662
3. Des Jarlais DC, Lyles C, Crepaz N, and the TREND Group. Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: the TREND statement. Am J Public Health 2004; 94:361-366
4. von Elm E. The STROBE statement. Available at: http://www.strobe- statement.org/. Accessed August 22, 2006
5. Durant RH. Checklist for the evaluation of research articles. J Adolesc Health 1994; 15:4-8
6. Altman DG. Statistical reviewing for medical journals. Stat Med 1998; 17:2661-2674
7. Instructions for preparing structured abstracts. JAMA 2005; 294:119-127
8. Lionel ND, Herxheimer A. Assessing reports of therapeutic trials. BMJ 1970; 3:637-640
9. Walker AM. Reporting the results of epidemic logical studies. Am J Public Health 1986; 76:556-558
10. Gifford RH, Feinstein AR. A critique of methodology in studies of anticoagulant therapy for acute myocardial infarction. N Engl J Med 1969; 280:351-357
11. Mahon WA, Daniel EE. A method for the assessment of reports of drug trials. Can Med Assoc J 1964; 90:565-569
12. Zelen M. Guidelines for publishing papers on cancer clinical trials: responsibilities of editors and authors. J Clin Oncol 1983; 1:164-169
13. Bhopal R, Donaldson L. White, European, Western Caucasian, or what? -inappropriate labeling in research on race, ethnicity, and health. Am J Public Health 1998; 88:1301-1307
14. Witzig R. The medicalization of race: scientific legitimization of a flawed social construct. Ann Intern Med 1996; 125:675-679
15. Bracken MB. Reporting observational studies. Br J Obstet Gynaecol 1989; 96:383-388
16. Haynes RB. How to read clinical journals: II. To learn about a diagnostic test. Can Med Assoc J 1981; 124:703-710
17. Tugwell PX. How to read clinical journals: III. To learn the clinical course and prognosis of disease. Can Med Assoc J 1981; 124:869-872
18. Davis NM, Cohen MR. Medication errors: causes and prevention. Philadelphia, PA: George Stickley Company, 1981
19. White SJ. Statistical errors in papers in the British Journal of Psychiatry. Br J Psychiatry 1979; 135:336-342
20. Felson DT, Anderson JJ, Meenan RF. Time for changes in the design, analysis, and reporting of rheumatoid arthritis clinical trials. Arthritis Rheum 1990; 33:140-149
21. Gotzsche PC. Methodology and overt and hidden bias in reports of 196 double-blind trials of nonsteroidal antiinflammatory drugs in rheumatoid arthritis. Control Clin Trials 1989; 10:31-56 [erratum appears in Control Clin Trials 1989; 50:356]
22. Bucher HC, Guyatt GH, Cook DJ, et al, for the Evidence-Based Medicine Working Group. User's guides to the medical literature XIX: Applying clinical trial results; A. How to use an article measuring the effect of an intervention on surrogate endpoints. JAMA 1999; 282:771-778
23. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being mislead? Ann Intern Med 1996; 125:605-613
24. Freeman KB, Back S, Bernstein J. Sample size and statistical power of randomized, controlled trials in orthopaedics. J Bone Joint Surg 2001; 83:397-402
25. Egger M, Juni P, Bartlett C, for the Consort Group. Value of flow diagrams in reports of randomized controlled trials. JAMA 2001; 285:1996-1999
26. Hollis S, Campbell F. What is meant by intention to treat analysis? Survey of published randomised controlled trials. BMJ 1999; 319:670-674
27. Grant A. Reporting controlled trials. Br J Obstet Gynaecol 1989; 96:397-400
28. Simon R, Wittes RE. Methodologic guidelines for reports of clinical trials. Cancer Treat Rep 1985; 69:1-3
29. Altman DG. Statistics and ethics in medical research: vIII. Improving the quality of statistics in medical journals. BMJ 1981; 282:44-47
30. Bailar JC III. Science, statistics, and deception. Ann Intern Med 1986; 104:259-260
31. Mills JL. Data torturing [letter]. N Engl J Med 1993; 329:1196-1199
32. Moskowitz G, Chalmers TC, Sacks HS, et al. Deficiencies of clinical trials of alcohol withdrawal. Alcohol Clin Exp Res 1983; 7:42-46
33. Ioannidis JPA, Lau J. Completeness of safety reporting in randomized trials. JAMA 2001; 285:437-443
34. Ethgen M, Boutron I, Baron G, et al. Reporting of harm in randomized, controlled trials of nonpharmacologic treatment for rheumatic disease. Ann Intern Med 2005; 143:20-25
35. Simon G, Wagner E, Vonkorff M. Cost-effectiveness comparisons using real world randomized trials: the case of new antidepressant drugs. J Clin Epidemiol 1995; 48:363-373
36. Goodman SN. Toward evidence-based medical statistics: 1. The P value fallacy. Ann Intern Med 1999; 130:995-1004